课题基金 / 基金详情

项目摘要

项目成果

JOSEPH Benjamin RUCKER的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Ion channels, such as Kv1.3 and Nav1.7, are involved in a number of human disorders, including autoimmunity and pain that affect >100 million Americans annually and are poorly treated. However, ion channels are typically exceptionally difficult to express at high levels due to their structural complexity and toxicity. s a result, many research and therapeutic applications for these targets have been very limited where high-levels of membrane protein are required. For example, for human voltage-gated potassium (Kv) and sodium (Nav) ion channels, there are no solved crystal structures and no therapeutic monoclonal antibodies (MAbs) approved by the FDA or even in clinical trials, despite the high level of pharmaceutical interest in such MAbs as therapeutics. These applications all typically require high levels of protein expression, and the expression of most ion channels is usually orders of magnitude below what is required for success. Here we propose to develop a versatile platform for expressing high levels of conformational ion channel proteins. Our use of this platform within the scope of this proposal will be for isolating unique MAbs against Kv1.3 and Nav1.7. We expect that this platform will be extensible to other ion channels and will also have utility for structural research, high-throughput screening, and as biomedical research reagents.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of Claudin MAbs for Treating Solid Tumors
  • 批准号:
    10482193
  • 项目类别:
  • 资助金额:
    $59.99万
  • 财政年份:
    2022
  • 负责人:
    JOSEPH Benjamin RUCKER
  • 依托单位:
Development of Claudin MAbs for Treating Solid Tumors
  • 批准号:
    10631161
  • 项目类别:
  • 资助金额:
    $70.93万
  • 财政年份:
    2022
  • 负责人:
    JOSEPH Benjamin RUCKER
  • 依托单位:
Development of Nav1.7 Monoclonal Antibodies for Treating Pain
  • 批准号:
    10318547
  • 项目类别:
  • 资助金额:
    $47.48万
  • 财政年份:
    2021
  • 负责人:
    JOSEPH Benjamin RUCKER
  • 依托单位:
Identifying Agonist MAbs against GPCRs
  • 批准号:
    9756430
  • 项目类别:
  • 资助金额:
    $13.22万
  • 财政年份:
    2018
  • 负责人:
    JOSEPH Benjamin RUCKER
  • 依托单位:
海外基金